Eli Lilly antibody drug fails in Covid-19 study

PTI Annapolis | Updated on October 27, 2020

US govt officials put early end to Lilly drug study on peole hospitalised with the virus

US government officials are putting an early end to a study testing an Eli Lilly antibody drug for people hospitalised with Covid-19 because it doesn’t seem to be helping them.

Independent monitors had paused enrolment in the study two weeks ago because of a possible safety issue.

But on Monday, the National Institute of Allergy and Infectious Diseases, which sponsors the study, said a closer look found no safety problem but a low chance that the drug would prove helpful for hospitalised patients.

Also read: Immunity of Covid-19 patients does not last long, shows a new study

It is a setback for one of the most promising treatment approaches for Covid-19. US President Donald Trump received a similar experimental antibody drug from Regeneron Pharmaceuticals Inc on an emergency basis when he was sickened with the coronavirus earlier this month.

In a statement Lilly noted that the US government is continuing a separate study testing the antibody drug in mild to moderately ill patients, to try to prevent hospitalisation and severe illness. The company is also continuing its own studies testing the drug, which is being developed with the Canadian company AbCellera.

Also read: Covid-19, a double whammy for chronic disease patients

Antibodies are proteins the body makes when an infection occurs; they attach to a virus and help it be eliminated.

The experimental drugs are concentrated versions of one or two specific antibodies that worked best against the coronavirus in lab and animal tests.

Lilly and Regeneron have asked the USFDA to grant emergency use authorisation for their drugs for Covid-19 while late-stage studies continue. Lilly says its request is based on other results that the drug is beneficial.

Published on October 27, 2020

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

This article is closed for comments.
Please Email the Editor

You May Also Like